DiaSorin S.p.A. (VIE:DIAS)

Market Cap	4.01B -28.3%
Revenue (ttm)	1.21B +2.7%
Net Income	184.11M -2.5%
EPS	3.41
Shares Out	n/a
PE Ratio	21.78
Forward PE	17.47
Dividend	1.20 (1.67%)
Ex-Dividend Date	May 19, 2025

Volume	n/a
Average Volume	361
Open	74.80
Previous Close	75.14
Day's Range	74.16 - 74.80
52-Week Range	58.60 - 103.80
Beta	n/a
RSI	62.13
Earnings Date	Mar 20, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,280
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: DIAS

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.